Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giovanni Maga

Showing results (171-180 of 214) with videos related to

Pageof 22
Sort By:
European Journal of Medicinal Chemistry|January 30, 2025
Corrigendum to "Applying molecular hybridization to design a new class of pyrazolo[3,4-d] pyrimidines as Src inhibitors active in hepatocellular carcinoma" [Eur. J. Med. Chem. 280 (2024) 116929]Salvatore Di Maria, Raffaele Passannanti, Federica Poggialini, et al.
Journal of Medicinal Chemistry|February 9, 2008
Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell linesFabrizio Manetti, Chiara Brullo, Matteo Magnani, et al.
Journal of Medicinal Chemistry|August 14, 2020
Unique Domain for a Unique Target: Selective Inhibitors of Host Cell DDX3X to Fight Emerging VirusesValentina Riva, Anna Garbelli, Annalaura Brai, et al.
European Journal of Medicinal Chemistry|October 15, 2024
Applying molecular hybridization to design a new class of pyrazolo[3,4-d]pyrimidines as Src inhibitors active in hepatocellular carcinomaSalvatore Di Maria, Raffaele Passannanti, Federica Poggialini, et al.
Journal of Medicinal Chemistry|March 14, 2009
Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virusFrancesco Piscitelli, Antonio Coluccia, Andrea Brancale, et al.
Journal of Medicinal Chemistry|March 30, 2011
Design, synthesis, biological activity, and ADME properties of pyrazolo[3,4-d]pyrimidines active in hypoxic human leukemia cells: a lead optimization studyMarco Radi, Elena Dreassi, Chiara Brullo, et al.
Journal of Medicinal Chemistry|June 4, 2015
Discovery of Multitarget Antivirals Acting on Both the Dengue Virus NS5-NS3 Interaction and the Host Src/Fyn KinasesPaolo Vincetti, Fabiana Caporuscio, Suzanne Kaptein, et al.
Journal of Medicinal Chemistry|June 11, 2013
Design, synthesis, and biological evaluation of pyrazolo[3,4-d]pyrimidines active in vivo on the Bcr-Abl T315I mutantMarco Radi, Cristina Tintori, Francesca Musumeci, et al.
European Journal of Medicinal Chemistry|May 24, 2020
DDX3X inhibitors, an effective way to overcome HIV-1 resistance targeting host proteinsAnnalaura Brai, Valentina Riva, Francesco Saladini, et al.
Journal of Medicinal Chemistry|June 17, 2014
Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymesDante Rotili, Domenico Tarantino, Maxim B Nawrozkij, et al.
Pageof 22

Showing results (171-180 of 214) with videos related to

Sort By:
Pageof 22
European Journal of Medicinal Chemistry|January 30, 2025
Corrigendum to "Applying molecular hybridization to design a new class of pyrazolo[3,4-d] pyrimidines as Src inhibitors active in hepatocellular carcinoma" [Eur. J. Med. Chem. 280 (2024) 116929]Salvatore Di Maria, Raffaele Passannanti, Federica Poggialini, et al.
Journal of Medicinal Chemistry|February 9, 2008
Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell linesFabrizio Manetti, Chiara Brullo, Matteo Magnani, et al.
Journal of Medicinal Chemistry|August 14, 2020
Unique Domain for a Unique Target: Selective Inhibitors of Host Cell DDX3X to Fight Emerging VirusesValentina Riva, Anna Garbelli, Annalaura Brai, et al.
European Journal of Medicinal Chemistry|October 15, 2024
Applying molecular hybridization to design a new class of pyrazolo[3,4-d]pyrimidines as Src inhibitors active in hepatocellular carcinomaSalvatore Di Maria, Raffaele Passannanti, Federica Poggialini, et al.
Journal of Medicinal Chemistry|March 14, 2009
Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virusFrancesco Piscitelli, Antonio Coluccia, Andrea Brancale, et al.
Journal of Medicinal Chemistry|March 30, 2011
Design, synthesis, biological activity, and ADME properties of pyrazolo[3,4-d]pyrimidines active in hypoxic human leukemia cells: a lead optimization studyMarco Radi, Elena Dreassi, Chiara Brullo, et al.
Journal of Medicinal Chemistry|June 4, 2015
Discovery of Multitarget Antivirals Acting on Both the Dengue Virus NS5-NS3 Interaction and the Host Src/Fyn KinasesPaolo Vincetti, Fabiana Caporuscio, Suzanne Kaptein, et al.
Journal of Medicinal Chemistry|June 11, 2013
Design, synthesis, and biological evaluation of pyrazolo[3,4-d]pyrimidines active in vivo on the Bcr-Abl T315I mutantMarco Radi, Cristina Tintori, Francesca Musumeci, et al.
European Journal of Medicinal Chemistry|May 24, 2020
DDX3X inhibitors, an effective way to overcome HIV-1 resistance targeting host proteinsAnnalaura Brai, Valentina Riva, Francesco Saladini, et al.
Journal of Medicinal Chemistry|June 17, 2014
Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymesDante Rotili, Domenico Tarantino, Maxim B Nawrozkij, et al.
Pageof 22